announcement

Announcement released

Living Cell Technologies Ltd
COMPANY ANNOUNCEMENT
Living Cell Technologies and US- Based Barbara Davis Center to collaborate on Diabetes Clinical Trial Program
February 27, 2008 – Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK) today announced that the Company has signed a term sheet with the Barbara Davis Center for Childhood Diabetes (BDC) to establish a diabetes clinical trial program in Denver, Colorado.
BDC and LCT will collaboratively pursue regulatory approval and then conduct a US clinical trial in type 1 diabetes with DiabeCell®, LCT's encapsulated porcine insulin producing cells. The proposed U.S. trial is planned to commence in 2009 and will be planned utilizing the clinical protocols and results from LCT's trials in Russia and New Zealand.
Professor George Eisenbarth, Professor of Medicine and Pediatrics at the BDC said: "The lack of adverse effects and the encouraging early clinical results from LCT's first Diabecell® trial have prompted us to do a trial in Denver."
Dr. Paul Tan, Chief Executive Officer of LCT added “We are pleased to have the extensive clinical trial capability of experts from one of the most established diabetes centers in the US to help us get DiabeCell® to people with diabetes.”
BDC is the largest diabetes and endocrine care program in Colorado. The Center is managed as a distinct administrative unit of the University of Colorado Denver School of Medicine.
BDC provides unique facilities and resources for clinicians, clinical researchers and basic biomedical scientists working to help patients with type I diabetes. The Center provides state-of-the-art clinical diabetes care to 80% of children in Colorado and many adults within the Rocky Mountain Region, as well as receiving national and international referrals.
Dr. Bob Elliott
Medical Director
Mob: +64 27 292 4177 Tel:+64 9 276 2690
[email protected]
Investor and Media Relations
Rebecca Wilson
Buchan Consulting
P:+612 9237 2800
M: +61 (0)417 382 391
[email protected]
Investor and Media Relations